Probi to launch gut and immune health products in Taiwan with Alvogen
Probi has signed a distribution agreement with Alvogen IPCO S.Á.R.L, a multi-national pharmaceutical company. Alvogen plans to launch Probi’s gut and immune health products on the Taiwanese market in Q1 2013.
“Alvogen is a multi-national company with offices in over 20 countries with ambitious plans for expansion in Asia. Taiwan is a very important market for Alvogen and we are very pleased that they will launch both our consumer healthcare products”, says Michael Oredsson, CEO of Probi.
Probi Digestis® is based on Lactobacillus plantarum 299v, which targets bloating, gas formation and pain, common symptoms that are sometimes mild or temporary but often more severe and diagnosed as IBS. Probi Defendum® is based on the combination of two probiotic strains, Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2. This probiotic mix has been proven in large clinical studies to prevent colds, significantly reduce cold symptoms and shorten cold periods.
Probi Digestis®will be launched under the brand Alvogen IBS and Probi Defendum®will be launched under Alvogen Contracold. Probi’s ingredient logotype will be featured on pack to emphasise the high quality probiotic ingredients. Both products will be sold via Alvogen’s field force targeting GPs and Gastroenterologists (Probi Digestis®) and GPs and Pediatricians (Probi Defendum®).
The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.
FOR FURTHER INFORMATION, CONTACT:
Michael Oredsson, CEO, Probi, phone +46 46 286 89 23 or mobile +46 707 18 89 30, e-mail: michael.oredsson@probi.se
Niklas Bjärum, Vice President Marketing & Sales, Probi, phone +46 46 286 89 67 or mobile +46 705 38 88 64, e-mail: niklas.bjarum@probi.se
ABOUT PROBI
Probi is a leading player in the probiotic research and the development of efficient and well-documented probiotics. The research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recovery. Probi’s customers are leading companies in the functional foods and consumer healthcare business areas. Total income for 2011 was MSEK 95.0. Probi’s share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 4,500 shareholders. For more information, please visit www.probi.com.
ABOUT ALVOGEN
Alvogen IPCO S.Á.R.L. is the next generation pharmaceuticals company. Our business model ensures competitive advantage through focused in-house capabilities and a network of partners for enhanced speed and flexibility. A unique portfolio of high quality and difficult to make products fuels our targeted growth strategy. Currently, Alvogen is in more than 20 countries around the world with over 200 strategically selected pharmaceutical projects in development and registration covering key therapeutic areas including biosimilars. Robert Wessman is Alvogen‘s Chairman and CEO and leads a world-class team with a proven industry track record aiming to build a top 10 global generics player.
Tags: